Ambulatory Medication Safety: Vaccination and Laboratory Screening for Patients Receiving Immunomodulatory Therapies
Authors' conclusion
More than 70% of patients were screened for either HBV, HCV, or TB at some point. Rates of pneumococcal vaccination were better than rates of influenza vaccination. Patients with in-system PCPs were more likely to be screened and vaccinated.
Study context
- Population
- Patients prescribed select immunosuppressive agents over 3 years at one institution, by rheumatology (52.6%) and non-rheumatology specialties
- Participants
- 2,396 patients
- Outcome
- Rates of HBV, HCV and TB screening and of pneumococcal and influenza vaccination, prior to initiation or at any time
Methodological detailssingle institution, logistic regression
- Single institution
- Logistic regression
Main finding
As reported in the abstract
Screening at any time point
Hepatitis B virus (HBV) screening
84.5%
2,025 of 2,396
Hepatitis C virus (HCV) screening
76.7%
1,838 of 2,396
Tuberculosis (TB) screening
71.8%
1,720 of 2,396
Observational data: associations, not effects.
Further findings
Predictors of pneumococcal vaccination
| OR (95% CI) | ||
|---|---|---|
| In-system PCP | 1.98 (1.55–2.54) | |
| Rheumatologist | 4.08 (2.76–6.02) | |
| 0.10.31310Odds ratio (log scale) |
Predictors of influenza vaccination
| OR (95% CI) | ||
|---|---|---|
| Dermatologic provider | 1.67 (1.14–2.45) | |
| Rheumatologic provider | 2.5 (1.86–3.36) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Ambulatory Medication Safety: Vaccination and Laboratory Screening for Patients Receiving Immunomodulatory Therapies. Arthritis Care Res (Hoboken). Published 5 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →